statistiche ricercatore

Continente	#
EU - Europa	15.284
NA - Nord America	945
AS - Asia	324
SA - Sud America	51
Continente sconosciuto - Info sul continente non disponibili	43
AF - Africa	12
OC - Oceania	1
Totale	16.660

Nazione	#
IT - Italia	15.097
US - Stati Uniti d'America	929
CN - Cina	124
SG - Singapore	107
UA - Ucraina	63
BR - Brasile	39
VN - Vietnam	39
SE - Svezia	37
GB - Regno Unito	24
FI - Finlandia	17
FR - Francia	16
DE - Germania	13
IN - India	10
CA - Canada	9
HK - Hong Kong	8
KR - Corea	7
AR - Argentina	6
BD - Bangladesh	6
ID - Indonesia	5
ES - Italia	4
KE - Kenya	4
AT - Austria	3
IQ - Iraq	3
JP - Giappone	3
MX - Messico	3
TR - Turchia	3
BE - Belgio	2
CO - Colombia	2
CR - Costa Rica	2
EC - Ecuador	2
MA - Marocco	2
PK - Pakistan	2
PL - Polonia	2
RU - Federazione Russa	2
AM - Armenia	1
AU - Australia	1
BS - Bahamas	1
CH - Svizzera	1
CL - Cile	1
DZ - Algeria	1
EE - Estonia	1
EG - Egitto	1
GT - Guatemala	1
IR - Iran	1
IS - Islanda	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LK - Sri Lanka	1
LT - Lituania	1
ML - Mali	1
NG - Nigeria	1
PY - Paraguay	1
SA - Arabia Saudita	1
TN - Tunisia	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	16.617

Nome	#
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy	3.586
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia	1.892
Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia	1.795
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia	1.726
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results	1.720
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy	1.693
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers	1.675
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers	1.484
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma	1.089
Totale	16.660

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	356	0	30	32	22	29	27	19	31	31	15	52	68
2022/2023	786	64	89	56	57	73	90	28	60	45	70	85	69
2023/2024	1.013	44	46	38	81	109	225	120	54	47	95	59	95
2024/2025	1.274	140	277	242	188	97	157	80	6	27	20	21	19
2025/2026	587	45	40	77	50	55	41	99	13	39	83	21	24
2026/2027	40	6	34	0	0	0	0	0	0	0	0	0	0
Totale													16.660

UNICA IRIS Institutional Research Information System